Mymetics Corp (MYMX) Financial Statements (2024 and earlier)

Company Profile

Business Address EUROPEAN EXECUTIVE OFFICE
EPALINGES, CH-1066
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments  335313401350122
Cash and cash equivalents  335313401350122
Receivables4286625854411
Prepaid expense49931061384477
Other undisclosed current assets402     
Total current assets:493514481597448610
Noncurrent Assets
Operating lease, right-of-use asset 27106133159186212
Property, plant and equipment32326303336
Intangible assets, net (including goodwill)  6,6716,6716,6716,6716,671
Goodwill  6,6716,6716,6716,6716,671
Deposits noncurrent assets 101010101010
Total noncurrent assets:406,8106,8406,8706,9006,929
TOTAL ASSETS:5337,3247,3217,4677,3487,539
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6599712134878423
Accounts payable6599712134878423
Debt   60,91560,03659,186
Due to related parties10,46110,1519,4958,841
Other undisclosed current liabilities74,18172,95161,356106121106
Total current liabilities:74,84073,92272,03071,22069,73068,556
Noncurrent Liabilities
Long-term debt and lease obligation144155156233252273
Long-term debt, excluding current maturities144155156176169164
Liabilities, other than long-term debt  4    
Operating lease, liability  4 5783109
Other undisclosed noncurrent liabilities   31(57)(83)(109)
Total noncurrent liabilities:144159187233252273
Total liabilities:74,98474,08172,21771,45369,98268,829
Equity
Equity, attributable to parent, including:(74,451)(66,757)(64,896)(63,986)(62,634)(61)
Common stock2,5302,5302,5302,5302,5302,530
Additional paid in capital34,44334,44334,44334,44334,44334,443
Accumulated other comprehensive income677686686689696698
Accumulated deficit(112,101)(104,416)(102,555)(101,648)(100,303)(98,961)
Other undisclosed equity, attributable to parent      61,229
Other undisclosed equity      (61,229)
Total equity:(74,451)(66,757)(64,896)(63,986)(62,634)(61,290)
TOTAL LIABILITIES AND EQUITY:5337,3247,3217,4677,3487,539

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues185277116130297485
Other income  2741,022  482
Cost of revenue (476)     
Other undisclosed gross profit   (1,331)   
Gross profit:(291)277(1,215)130297485
Operating expenses (1,478)728(529)(727)(914)
Operating loss:(291)(1,201)(487)(399)(430)(429)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
   (284)243(213)88
Interest and debt expense(711)(697)(704)(703)(699)(694)
Loss from continuing operations before equity method investments, income taxes:(1,002)(1,898)(1,475)(859)(1,342)(1,035)
Other undisclosed income (loss) from continuing operations before income taxes(6,683)37568(486) (176)
Loss from continuing operations:(7,685)(1,861)(907)(1,345)(1,342)(1,211)
Loss before gain (loss) on sale of properties:(1,345)(1,342)(1,211)
Other undisclosed net income (loss)  3,722(7,796)  2,422
Net income (loss):(7,685)1,861(8,703)(1,345)(1,342)1,211
Other undisclosed net income (loss) attributable to parent  (3,722)7,796  (1,212)
Net loss available to common stockholders, diluted:(7,685)(1,861)(907)(1,345)(1,342)(1)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(7,685)1,861(8,703)(1,345)(1,342)1,211
Other comprehensive income (loss)7,6941,8614,812(7)  
Comprehensive income (loss):93,722(3,891)(1,352)(1,342)1,211
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   7,796 (2)(2,415)
Comprehensive income (loss), net of tax, attributable to parent:93,7223,905(1,352)(1,344)(1,204)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: